Search results
Showing 1006 to 1020 of 1026 results for drug therapy
A number of commonly used drug treatments for chronic primary pain have little or no evidence that they work and shouldn’t be prescribed, NICE has said in its draft clinical guideline published today (3 August 2020) on the assessment and management of chronic pain in over 16s.
NICE recommends new 'chemotherapy-free' treatment for lymphoma
A new treatment option for patients with previously treated follicular lymphoma (grade 1 to 3A) has been approved by NICE.
NICE recommends new drug osimertinib for hundreds of people with lung cancer
Hundreds of people with lung cancer will now have access to new drug osimertinib, also known as Tagrisso, after NICE says it should be made available on the Cancer Drugs Fund (CDF).
NICE recommends Piqray and Trodelvy, maintaining 100% approvals of breast cancer drugs since 2018
An agreement with the companies on the price of 2 breast cancer treatments, Piqray and Trodelvy, has paved the way for NICE to be able to make them available immediately to around 3,450 people on the NHS and maintaining NICE’s 100% approval rate of breast cancer drugs since 2018.
People with chronic primary pain should be offered a range of treatments to help them manage their condition, NICE has said in its guideline on the assessment and management of chronic pain published today (7 April).
NICE recommends several treatment options to help thousands with moderate rheumatoid arthritis
Around 25,000 people with moderate rheumatoid arthritis that has not responded to conventional therapies are set to benefit from the recommendations announced today
NICE recommends step-change targeted treatment for people with early breast cancer
Around 4,000 people are set to benefit from a step-change in treatment for early breast cancer following today’s (17 June 2022) provisional approval by NICE of abemaciclib in combination with hormone therapy as an option after surgery.
NICE recommends treatment for people with juvenile idiopathic arthritis
NICE has today (9 September 2021) published final draft guidance which recommends tofacitinib (also known as Xeljanz and made by Pfizer) as an option for treating active polyarticular juvenile arthritis and juvenile psoriatic arthritis in people 2 years and older.
NICE says new triple negative advanced breast cancer drug too expensive for NHS use
NICE has today, 7 April 2022, issued draft guidance which does not recommend sacituzumab govitecan for treating locally advanced or metastatic triple negative breast cancer.
NICE recommends cutting-edge therapy for young people with blood cancer
NICE has recommended a pioneering cancer treatment, CART-cell therapy, for people under the age of 25 with leukaemia.
People with a rare condition that steadily worsens often leaving them dependent on a wheelchair and with shortened life expectancy, can now benefit from the first treatment to slow its progression.
NICE has today (9 April 2020) published 3 new rapid guidelines on the care of patients with suspected and confirmed COVID-19, and in patients without COVID-19. The guidelines have been designed to maximise the safety of patients whilst enabling services to make the best use of NHS resources.
Novel oral anticoagulants an option for patients with atrial fibrillation
Offering patients anticoagulants could help prevent thousands of strokes and premature deaths from atrial fibrillation (AF), according to NICE.
Wireless device recommended for treating people with overactive bladder
Axonics SNS has potential to save the NHS around £6,200 per patient if the device lasts more than six years
Triple therapy recommended by NICE for patients with multiple myeloma
The therapy has been recommended after a confidential discount was agreed between NHS England and the drug manufacturer Amgen.